Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
223 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diabetic Retinopathy - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Diabetic Retinopathy - Pipeline Review, H1 2016', provides an overview of the Diabetic Retinopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy - The report reviews pipeline therapeutics for Diabetic Retinopathy by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Diabetic Retinopathy therapeutics and enlists all their major and minor projects - The report assesses Diabetic Retinopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Diabetic Retinopathy Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Diabetic Retinopathy Overview 9 Therapeutics Development 10 Pipeline Products for Diabetic Retinopathy - Overview 10 Pipeline Products for Diabetic Retinopathy - Comparative Analysis 11 Diabetic Retinopathy - Therapeutics under Development by Companies 12 Diabetic Retinopathy - Therapeutics under Investigation by Universities/Institutes 15 Diabetic Retinopathy - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Diabetic Retinopathy - Products under Development by Companies 19 Diabetic Retinopathy - Products under Investigation by Universities/Institutes 23 Diabetic Retinopathy - Companies Involved in Therapeutics Development 24 Acucela Inc. 24 Aerie Pharmaceuticals, Inc. 25 Aerpio Therapeutics, Inc. 26 Antisense Therapeutics Limited 27 BCN Peptides, S.A. 28 Biomar Microbial Technologies 29 Charlesson LLC. 30 Coherus BioSciences, Inc. 31 Crinetics Pharmaceuticals, Inc. 32 Diffusion Pharmaceuticals Inc. 33 Dimerix Bioscience Pty Ltd 34 Dynamis Therapeutics, Inc. 35 EyeGene, Inc. 36 Foresee Pharmaceuticals, LLC 37 GTx, Inc. 38 Icon Bioscience, Inc. 39 Islet Sciences, Inc. 40 Kodiak Sciences, Inc. 41 Kowa Company, Ltd. 42 LegoChem Biosciences, Inc 43 Lpath, Inc. 44 M's Science Corporation 45 Mabion SA 46 MingSight Pharmaceuticals 47 OcuCure Therapeutics, Inc. 48 Oculis ehf 49 Ohr Pharmaceutical Inc. 50 PanOptica, Inc. 51 Promedior, Inc. 52 Ribomic Inc. 53 Sirnaomics, Inc. 54 Stelic Institute & Co., Inc. 55 Stemedica Cell Technologies, Inc. 56 Strongbridge Biopharma plc 57 Sucampo Pharmaceuticals, Inc. 58 Targazyme, Inc. 59 ThromboGenics NV 60 TWi Pharmaceuticals, Inc. 61 UAB Profarma 62 VasGene Therapeutics, Inc. 63 Xbrane Biopharma AB 64 Diabetic Retinopathy - Therapeutics Assessment 65 Assessment by Monotherapy Products 65 Assessment by Combination Products 66 Assessment by Target 67 Assessment by Mechanism of Action 70 Assessment by Route of Administration 73 Assessment by Molecule Type 75 Drug Profiles 77 (irbesartan + propagermanium) - Drug Profile 77 A-717 - Drug Profile 79 AC-301 - Drug Profile 80 AKB-9778 - Drug Profile 81 ALG-1001 - Drug Profile 83 APTA-1004 - Drug Profile 85 Aptamers for Diabetic Retinopathy - Drug Profile 86 AR-13154 - Drug Profile 87 ATL-1103 - Drug Profile 88 Beta-LGND2 - Drug Profile 90 Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile 92 CLT-005 - Drug Profile 93 CLT-01001 - Drug Profile 94 CLT-01007 - Drug Profile 95 CLT-01012 - Drug Profile 96 CLT-020 - Drug Profile 97 COR-005 - Drug Profile 98 cyclosporine - Drug Profile 101 Cyndacel-M - Drug Profile 102 DMX-400 - Drug Profile 104 Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy - Drug Profile 105 DT-23552 - Drug Profile 106 DYN-12 - Drug Profile 107 E-1086 - Drug Profile 109 EG-Mirotin - Drug Profile 110 emixustat hydrochloride - Drug Profile 112 FP-008 - Drug Profile 114 Granzyme B/VEGF - Drug Profile 115 IB-09A0133 - Drug Profile 116 IVMED-60 - Drug Profile 117 JP-153 - Drug Profile 118 KSI-301 - Drug Profile 119 L-779976 - Drug Profile 120 LCB-030110 - Drug Profile 122 Monoclonal Antibody for AMD, Diabetic Retinopathy and Oncology - Drug Profile 123 Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile 124 MS-553 - Drug Profile 125 Nextomabs - Drug Profile 126 NM-108 - Drug Profile 127 OC-10X - Drug Profile 128 OC-410 - Drug Profile 129 ocriplasmin (recombinant) - Drug Profile 130 OCU-200 - Drug Profile 134 OCX-063 - Drug Profile 135 OLX-302 - Drug Profile 136 PAN-90806 - Drug Profile 137 PF-07 - Drug Profile 139 PRM-167 - Drug Profile 140 Protein for Oncology, Ophthalmology and Metabolic Disorders - Drug Profile 141 ranibizumab biosimilar - Drug Profile 142 ranibizumab biosimilar - Drug Profile 143 ranibizumab biosimilar - Drug Profile 144 RBM-008 - Drug Profile 145 Recombinant Protein for Cancer and Diabetic Retinopathy - Drug Profile 146 RES-529 - Drug Profile 147 ripasudil - Drug Profile 150 RTU-1096 - Drug Profile 152 somatostatin - Drug Profile 153 squalamine lactate - Drug Profile 154 Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 157 Stem Cell Therapy for Diabetic Retinopathy - Drug Profile 160 STNM-1510 - Drug Profile 161 STP-601 - Drug Profile 162 Synthetic Peptide to Agonize PEDF-R for Diabetic Retinopathy - Drug Profile 163 THR-687 - Drug Profile 164 TZ-101 - Drug Profile 165 V-1932 - Drug Profile 167 Vas-02 - Drug Profile 168 Diabetic Retinopathy - Recent Pipeline Updates 169 Diabetic Retinopathy - Dormant Projects 203 Diabetic Retinopathy - Discontinued Products 209 Diabetic Retinopathy - Product Development Milestones 210 Featured News & Press Releases 210 Appendix 217 Methodology 217 Coverage 217 Secondary Research 217 Primary Research 217 Expert Panel Validation 217 Contact Us 217 Disclaimer 218
List of Tables
Number of Products under Development for Diabetic Retinopathy, H1 2016 15 Number of Products under Development for Diabetic Retinopathy - Comparative Analysis, H1 2016 16 Number of Products under Development by Companies, H1 2016 17 Number of Products under Development by Companies, H1 2016 (Contd..1) 18 Number of Products under Development by Companies, H1 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H1 2016 20 Comparative Analysis by Clinical Stage Development, H1 2016 21 Comparative Analysis by Early Stage Development, H1 2016 22 Comparative Analysis by Unknown Stage Development, H1 2016 23 Products under Development by Companies, H1 2016 24 Products under Development by Companies, H1 2016 (Contd..1) 25 Products under Development by Companies, H1 2016 (Contd..2) 26 Products under Development by Companies, H1 2016 (Contd..3) 27 Products under Investigation by Universities/Institutes, H1 2016 28 Diabetic Retinopathy - Pipeline by Acucela Inc., H1 2016 29 Diabetic Retinopathy - Pipeline by Aerie Pharmaceuticals, Inc., H1 2016 30 Diabetic Retinopathy - Pipeline by Aerpio Therapeutics, Inc., H1 2016 31 Diabetic Retinopathy - Pipeline by Antisense Therapeutics Limited, H1 2016 32 Diabetic Retinopathy - Pipeline by BCN Peptides, S.A., H1 2016 33 Diabetic Retinopathy - Pipeline by Biomar Microbial Technologies, H1 2016 34 Diabetic Retinopathy - Pipeline by Charlesson LLC., H1 2016 35 Diabetic Retinopathy - Pipeline by Coherus BioSciences, Inc., H1 2016 36 Diabetic Retinopathy - Pipeline by Crinetics Pharmaceuticals, Inc., H1 2016 37 Diabetic Retinopathy - Pipeline by Diffusion Pharmaceuticals Inc., H1 2016 38 Diabetic Retinopathy - Pipeline by Dimerix Bioscience Pty Ltd, H1 2016 39 Diabetic Retinopathy - Pipeline by Dynamis Therapeutics, Inc., H1 2016 40 Diabetic Retinopathy - Pipeline by EyeGene, Inc., H1 2016 41 Diabetic Retinopathy - Pipeline by Foresee Pharmaceuticals, LLC, H1 2016 42 Diabetic Retinopathy - Pipeline by GTx, Inc., H1 2016 43 Diabetic Retinopathy - Pipeline by Icon Bioscience, Inc., H1 2016 44 Diabetic Retinopathy - Pipeline by Islet Sciences, Inc., H1 2016 45 Diabetic Retinopathy - Pipeline by Kodiak Sciences, Inc., H1 2016 46 Diabetic Retinopathy - Pipeline by Kowa Company, Ltd., H1 2016 47 Diabetic Retinopathy - Pipeline by LegoChem Biosciences, Inc, H1 2016 48 Diabetic Retinopathy - Pipeline by Lpath, Inc., H1 2016 49 Diabetic Retinopathy - Pipeline by M's Science Corporation, H1 2016 50 Diabetic Retinopathy - Pipeline by Mabion SA, H1 2016 51 Diabetic Retinopathy - Pipeline by MingSight Pharmaceuticals, H1 2016 52 Diabetic Retinopathy - Pipeline by OcuCure Therapeutics, Inc., H1 2016 53 Diabetic Retinopathy - Pipeline by Oculis ehf, H1 2016 54 Diabetic Retinopathy - Pipeline by Ohr Pharmaceutical Inc., H1 2016 55 Diabetic Retinopathy - Pipeline by PanOptica, Inc., H1 2016 56 Diabetic Retinopathy - Pipeline by Promedior, Inc., H1 2016 57 Diabetic Retinopathy - Pipeline by Ribomic Inc., H1 2016 58 Diabetic Retinopathy - Pipeline by Sirnaomics, Inc., H1 2016 59 Diabetic Retinopathy - Pipeline by Stelic Institute & Co., Inc., H1 2016 60 Diabetic Retinopathy - Pipeline by Stemedica Cell Technologies, Inc., H1 2016 61 Diabetic Retinopathy - Pipeline by Strongbridge Biopharma plc , H1 2016 62 Diabetic Retinopathy - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 63 Diabetic Retinopathy - Pipeline by Targazyme, Inc., H1 2016 64 Diabetic Retinopathy - Pipeline by ThromboGenics NV, H1 2016 65 Diabetic Retinopathy - Pipeline by TWi Pharmaceuticals, Inc., H1 2016 66 Diabetic Retinopathy - Pipeline by UAB Profarma, H1 2016 67 Diabetic Retinopathy - Pipeline by VasGene Therapeutics, Inc., H1 2016 68 Diabetic Retinopathy - Pipeline by Xbrane Biopharma AB, H1 2016 69 Assessment by Monotherapy Products, H1 2016 70 Assessment by Combination Products, H1 2016 71 Number of Products by Stage and Target, H1 2016 73 Number of Products by Stage and Mechanism of Action, H1 2016 76 Number of Products by Stage and Route of Administration, H1 2016 79 Number of Products by Stage and Molecule Type, H1 2016 81 Diabetic Retinopathy Therapeutics - Recent Pipeline Updates, H1 2016 174 Diabetic Retinopathy - Dormant Projects, H1 2016 208 Diabetic Retinopathy - Dormant Projects (Contd..1), H1 2016 209 Diabetic Retinopathy - Dormant Projects (Contd..2), H1 2016 210 Diabetic Retinopathy - Dormant Projects (Contd..3), H1 2016 211 Diabetic Retinopathy - Dormant Projects (Contd..4), H1 2016 212 Diabetic Retinopathy - Dormant Projects (Contd..5), H1 2016 213 Diabetic Retinopathy - Discontinued Products, H1 2016 214
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
